Frequently Asked Questions
The global biologic imaging reagents market was valued at USD 16.5 Billion in 2022.
The biologic imaging reagents market is anticipated to grow at a CAGR of 8.70% between 2023 and 2030, reaching USD 29.59 Billion in 2030.
Contrast reagents are the leading segment by class, holding over 39% share in terms of value in 2022.
The optical imaging segment governs the demand for biologic imaging reagents worldwide, holding a massive share of over 32% in 2022.
The in vitro segment will post the highest CAGR in the projected period.
Asia Pacific is fuelling the rapid growth of the biologic imaging reagents industry, with an over one-third share in 2022.
The top players include Thermo Fisher Scientific, Bracco Diagnostic Inc, Cardinal Health, and Siemens. Other major players include Bayer, FUJIFILM VisualSonics Inc, Koninklijke Philips N.V., and Promega Corporation.
The major market drivers are the advancements in imaging technologies, emerging demands for personalized medicine, rising research activities in life sciences, and the growing prevalence of chronic diseases.
The major market restraints are the high cost of imaging reagents, stringent regulatory requirements, limited reimbursement policies, and ethical concerns related to certain imaging agents.
The major market opportunities of the biologic imaging reagents industry lie in the expanding applications in drug discovery and development, emerging imaging modalities and technologies, and the potential for collaborations and partnerships to drive innovation and market growth.